Marijt W A, Veenhof W F, Brand A, Goulmy E, Fibbe W E, Willemze R, van Rood J J, Falkenburg J H
Laboratory of Experimental Hematology, University Medical Center, Leiden, The Netherlands.
J Exp Med. 1991 Jan 1;173(1):101-9. doi: 10.1084/jem.173.1.101.
Recipient-antidonor alloreactivity before HLA genotypically identical bone marrow transplantation (BMT) between donor-recipient pairs that are negative in the mixed lymphocyte reaction (MLR), the cell-mediated lympholysis (CML) assay, and the lymphocyte crossmatch was not detectable in the majority of cases, using recipient peripheral blood lymphocytes (PBL) collected before BMT as responder cells and donor PBL as stimulator cells. However, when donor bone marrow mononuclear cells (BMMNC) instead of PBL were used as stimulator cells, we could detect donor-specific alloreactivity in 7 of 10 HLA genotypically identical donor-recipient pairs. To demonstrate that this alloreactivity was minor histocompatibility (mH) antigen specific and not directed against HLA class I splits or variants, two cytotoxic T lymphocyte (CTL) lines were tested in further detail against phytohemagglutinin (PHA) blasts from pairs of HLA genotypically identical siblings positive for the HLA class I restriction molecule. Both CTL lines recognized mH antigens, as illustrated by the differential recognition of PHA blasts of one of the two siblings from several pairs. The potential role of these mH antigen-specific CTLs in bone marrow graft rejection was demonstrated by the mH antigen-specific growth inhibition of hematopoietic progenitor cells from the original bone marrow donor and from HLA class I restriction molecule-positive individuals who expressed the mH antigens on their PBL and BMMNC. Our assay can be used in HLA genotypically identical BMT to detect a recipient-antidonor response, directed against cellularly defined mH antigens expressed on donor HPC, BMMNC, and PBL, before transplantation.
在混合淋巴细胞反应(MLR)、细胞介导的淋巴细胞溶解(CML)试验及淋巴细胞交叉配型均为阴性的供受者对之间进行HLA基因分型相同的骨髓移植(BMT)前,多数情况下无法检测到受者对供者的同种异体反应性,该反应性检测采用BMT前采集的受者外周血淋巴细胞(PBL)作为反应细胞、供者PBL作为刺激细胞。然而,当使用供者骨髓单个核细胞(BMMNC)而非PBL作为刺激细胞时,在10对HLA基因分型相同的供受者对中,有7对可检测到供者特异性同种异体反应性。为证明这种同种异体反应性是针对次要组织相容性(mH)抗原而非针对HLA I类分裂产物或变体,对两条细胞毒性T淋巴细胞(CTL)系针对来自HLA基因分型相同的同胞对且HLA I类限制性分子呈阳性的植物血凝素(PHA)刺激的淋巴细胞进行了更详细的检测。两条CTL系均识别mH抗原,如几对同胞对中其中一位同胞的PHA刺激的淋巴细胞存在差异识别所示。这些mH抗原特异性CTL在骨髓移植排斥中的潜在作用通过对来自原始骨髓供者以及在其PBL和BMMNC上表达mH抗原的HLA I类限制性分子阳性个体的造血祖细胞的mH抗原特异性生长抑制得以证明。我们的检测方法可用于HLA基因分型相同的BMT,以在移植前检测针对供者造血祖细胞、BMMNC和PBL上细胞界定的mH抗原的受者对供者反应。